Abbott reports strong start to 2017 with double-digit Q1 growth

Abbott has announced its financial results for the first quarter of 2017, with worldwide sales reaching a total of $6.3 billion (4.92 billion pounds) during the period.

This represents a year-on-year increase of 29.7 percent on a year-on-year basis, or a 3.2 percent increase in comparable operational terms. The completion of Abbott's takeover of St Jude Medical in January was a key growth driver.

The company expressed satisfaction with its strong performance during Q1, which saw the firm receive US market approval for the Assurity MRI pacemaker and the Tendril MRI pacing lead, as well as introducing its Ensite Precision cardiac mapping system in the US.

It is expected that the St Jude Medical deal will establish Abbott as a leader in the broad medical device arena and provide the company with expanded opportunities for future growth.

Based on its performance during the first quarter, the firm has left its full-year earnings per share guidance unchanged.

Miles White, chairman and chief executive officer of Abbott, said: "The integration of St Jude is going well and recently launched products are contributing to double-digit sales growth across several areas of our medical devices business."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.